|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FANCC |
Gene summary for FANCC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FANCC | Gene ID | 2176 |
| Gene name | FA complementation group C | |
| Gene Alias | FA3 | |
| Cytomap | 9q22.32 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R9N2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2176 | FANCC | CCI_1 | Human | Cervix | CC | 3.73e-22 | 9.27e-01 | 0.528 |
| 2176 | FANCC | CCI_2 | Human | Cervix | CC | 1.66e-20 | 1.40e+00 | 0.5249 |
| 2176 | FANCC | CCI_3 | Human | Cervix | CC | 1.78e-34 | 1.51e+00 | 0.516 |
| 2176 | FANCC | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.13e-06 | 6.54e-01 | 0.343 |
| 2176 | FANCC | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.48e-03 | 4.04e-01 | 0.3385 |
| 2176 | FANCC | RNA-P17T-P17T-8 | Human | Lung | IAC | 1.77e-07 | 6.15e-01 | 0.3329 |
| 2176 | FANCC | RNA-P23T2-P23T2-4 | Human | Lung | MIAC | 3.47e-02 | 6.90e-01 | -0.0272 |
| 2176 | FANCC | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.26e-04 | 2.01e-01 | -0.0166 |
| 2176 | FANCC | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.03e-05 | 2.18e-01 | -0.013 |
| 2176 | FANCC | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 2.01e-02 | 1.65e-01 | -0.0121 |
| 2176 | FANCC | HTA12-23-1 | Human | Pancreas | PDAC | 1.44e-05 | 6.13e-01 | 0.3405 |
| 2176 | FANCC | HTA12-25-1 | Human | Pancreas | PDAC | 3.07e-08 | 6.03e-01 | 0.313 |
| 2176 | FANCC | HTA12-26-1 | Human | Pancreas | PDAC | 1.01e-13 | 6.52e-01 | 0.3728 |
| 2176 | FANCC | HTA12-29-1 | Human | Pancreas | PDAC | 5.38e-40 | 8.10e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000697910 | Cervix | CC | response to oxidative stress | 102/2311 | 446/18723 | 2.99e-10 | 4.36e-08 | 102 |
| GO:000030210 | Cervix | CC | response to reactive oxygen species | 56/2311 | 222/18723 | 1.00e-07 | 5.25e-06 | 56 |
| GO:006219710 | Cervix | CC | cellular response to chemical stress | 76/2311 | 337/18723 | 1.01e-07 | 5.25e-06 | 76 |
| GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
| GO:00988699 | Cervix | CC | cellular oxidant detoxification | 30/2311 | 101/18723 | 2.72e-06 | 7.93e-05 | 30 |
| GO:003459910 | Cervix | CC | cellular response to oxidative stress | 63/2311 | 288/18723 | 3.58e-06 | 9.50e-05 | 63 |
| GO:19907489 | Cervix | CC | cellular detoxification | 30/2311 | 116/18723 | 5.34e-05 | 7.94e-04 | 30 |
| GO:00972379 | Cervix | CC | cellular response to toxic substance | 31/2311 | 124/18723 | 8.09e-05 | 1.10e-03 | 31 |
| GO:003461410 | Cervix | CC | cellular response to reactive oxygen species | 35/2311 | 155/18723 | 2.59e-04 | 2.85e-03 | 35 |
| GO:00096369 | Cervix | CC | response to toxic substance | 52/2311 | 262/18723 | 3.34e-04 | 3.52e-03 | 52 |
| GO:00725939 | Cervix | CC | reactive oxygen species metabolic process | 47/2311 | 239/18723 | 7.74e-04 | 6.87e-03 | 47 |
| GO:00987549 | Cervix | CC | detoxification | 33/2311 | 152/18723 | 7.97e-04 | 7.00e-03 | 33 |
| GO:00987275 | Cervix | CC | maintenance of cell number | 30/2311 | 134/18723 | 7.98e-04 | 7.00e-03 | 30 |
| GO:00198274 | Cervix | CC | stem cell population maintenance | 29/2311 | 131/18723 | 1.17e-03 | 9.47e-03 | 29 |
| GO:0006801 | Cervix | CC | superoxide metabolic process | 17/2311 | 74/18723 | 7.73e-03 | 4.10e-02 | 17 |
| GO:00069798 | Lung | IAC | response to oxidative stress | 82/2061 | 446/18723 | 1.99e-06 | 9.18e-05 | 82 |
| GO:00022628 | Lung | IAC | myeloid cell homeostasis | 37/2061 | 157/18723 | 5.42e-06 | 2.09e-04 | 37 |
| GO:00621978 | Lung | IAC | cellular response to chemical stress | 64/2061 | 337/18723 | 8.92e-06 | 3.01e-04 | 64 |
| GO:00488728 | Lung | IAC | homeostasis of number of cells | 54/2061 | 272/18723 | 1.20e-05 | 3.64e-04 | 54 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FANCC | SNV | Missense_Mutation | rs768508859 | c.1081N>T | p.Arg361Trp | p.R361W | Q00597 | protein_coding | deleterious(0.01) | benign(0.417) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| FANCC | SNV | Missense_Mutation | c.19N>T | p.Asp7Tyr | p.D7Y | Q00597 | protein_coding | tolerated(1) | possibly_damaging(0.459) | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |
| FANCC | SNV | Missense_Mutation | rs369636116 | c.1664N>A | p.Arg555Gln | p.R555Q | Q00597 | protein_coding | tolerated(0.59) | benign(0.001) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FANCC | insertion | In_Frame_Ins | novel | c.848_849insTTGCCTGTCGAGAGTGGTGCTGGT | p.Gln283delinsHisCysLeuSerArgValValLeuVal | p.Q283delinsHCLSRVVLV | Q00597 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| FANCC | insertion | In_Frame_Ins | novel | c.1128_1129insCTGGTG | p.Arg376_Glu377insLeuVal | p.R376_E377insLV | Q00597 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| FANCC | insertion | Frame_Shift_Ins | novel | c.1127_1128insGTGGCCACATGGGACTGCTTGTGCATTCAGCT | p.Glu377TrpfsTer11 | p.E377Wfs*11 | Q00597 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| FANCC | SNV | Missense_Mutation | c.175N>G | p.Thr59Ala | p.T59A | Q00597 | protein_coding | tolerated(0.67) | benign(0.003) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FANCC | SNV | Missense_Mutation | rs371897078 | c.1162N>A | p.Gly388Arg | p.G388R | Q00597 | protein_coding | tolerated(0.39) | benign(0.012) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| FANCC | SNV | Missense_Mutation | rs369636116 | c.1664G>A | p.Arg555Gln | p.R555Q | Q00597 | protein_coding | tolerated(0.59) | benign(0.001) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FANCC | SNV | Missense_Mutation | c.1337N>A | p.Val446Glu | p.V446E | Q00597 | protein_coding | tolerated(0.06) | possibly_damaging(0.601) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | MITOMYCIN | MITOMYCIN | 16243825 | |
| 2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | CHLORAMBUCIL | CHLORAMBUCIL | 16243825 | |
| 2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | CISPLATIN | CISPLATIN | 16243825 | |
| 2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | MELPHALAN | MELPHALAN | 16243825 | |
| 2176 | FANCC | CLINICALLY ACTIONABLE, DNA REPAIR | GEMCITABINE | GEMCITABINE | 16243825 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |